Zura reports Phase 2 flop in painful skin disorder, stock nosedives
A small biotech’s stock collapsed after the company reported a Phase 2 failure in a debilitating skin condition. Zura Bio said Monday morning that both doses of its experimental drug tibulizumab fared no better than ...
Zura Bio's Phase 2 trial for tibulizumab in treating hidradenitis suppurativa has failed to meet its primary endpoint, according to a press release. The trial, which enrolled 247 participants, did not show a statistically significant difference in the reduction of abscess and inflammatory nodule count between the tibulizumab treatment groups and the placebo group.
Despite this setback, the company's safety profile of tibulizumab was found to be consistent with inhibition of IL-17 and BAFF. Zura Bio will discontinue development of tibulizumab for this skin disease but will continue trials in systemic sclerosis and polymyalgia rheumatica.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
